AU2002248909A1 - Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition - Google Patents
Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibitionInfo
- Publication number
- AU2002248909A1 AU2002248909A1 AU2002248909A AU4890902A AU2002248909A1 AU 2002248909 A1 AU2002248909 A1 AU 2002248909A1 AU 2002248909 A AU2002248909 A AU 2002248909A AU 4890902 A AU4890902 A AU 4890902A AU 2002248909 A1 AU2002248909 A1 AU 2002248909A1
- Authority
- AU
- Australia
- Prior art keywords
- suramine
- cycloserine
- histidine
- angiogenesis inhibition
- quisqualic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 title 2
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 title 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 title 1
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 title 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 title 1
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 title 1
- 230000033115 angiogenesis Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 title 1
- 229960005314 suramin Drugs 0.000 title 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Composite Materials (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24886500P | 2000-11-15 | 2000-11-15 | |
| US60/248,865 | 2000-11-15 | ||
| US27792201P | 2001-03-22 | 2001-03-22 | |
| US60/277,922 | 2001-03-22 | ||
| PCT/US2001/046221 WO2002039999A2 (en) | 2000-11-15 | 2001-11-15 | Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002248909A1 true AU2002248909A1 (en) | 2002-05-27 |
Family
ID=26939634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002248909A Abandoned AU2002248909A1 (en) | 2000-11-15 | 2001-11-15 | Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US20020156112A1 (en) |
| AU (1) | AU2002248909A1 (en) |
| WO (1) | WO2002039999A2 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2404858A1 (en) * | 2000-04-12 | 2001-10-25 | Minerva Biotechnologies Corporation | Treatment of neurodegenerative disease |
| JP4223804B2 (en) | 2000-10-03 | 2009-02-12 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | In situ dilution with magnetic force |
| US20020164611A1 (en) * | 2000-11-15 | 2002-11-07 | Bamdad R. Shoshana | Oligonucleotide identifiers |
| AU2002248909A1 (en) * | 2000-11-15 | 2002-05-27 | Minerva Biotechnologies Corporation | Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition |
| WO2002056022A2 (en) | 2000-11-27 | 2002-07-18 | Minerva Biotechnologies Corp | Diagnostics, drug screening and treatment for cancer |
| US7750030B2 (en) | 2001-03-29 | 2010-07-06 | Michael Davis | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| US20060173171A1 (en) * | 2003-08-26 | 2006-08-03 | Bamdad Cynthia C | Techniques and compositions for diagnosis and treatment of cancer (muci) |
| JP5635726B2 (en) * | 2004-09-14 | 2014-12-03 | ミネルバ バイオテクノロジーズ コーポレーション | Cancer diagnosis and treatment method |
| ITMI20070817A1 (en) | 2007-04-19 | 2008-10-20 | Farmacetika Ltd | PHARMACEUTICAL COMPOSITION INCLUDING L-CARNITINE AND AN ANTAGONIST AGENT OF MEMBRANE ADENOSIN RECEPTORS, THEIR DERIVATIVES AND / OR PHARMACEUTICALLY ACCEPTABLE SALTS, AND USE OF THE SAME IN THE PREPARATION OF DRUGS WITH NON-TOXIC EFFECT OF INIBI |
| KR20140101876A (en) | 2008-10-09 | 2014-08-20 | 미네르바 바이오테크놀로지 코포레이션 | Method for inducing pluripotency in cells |
| US20110245311A1 (en) * | 2009-04-03 | 2011-10-06 | Dennis Wright | Histidine Derivatives |
| JP6196163B2 (en) | 2011-03-17 | 2017-09-13 | ミネルバ バイオテクノロジーズ コーポレーション | Methods for producing pluripotent stem cells |
| AU2016219350A1 (en) | 2015-02-10 | 2017-08-24 | Minerva Biotechnologies Corporation | Humanized anti-MUC1* antibodies |
| JP2019151621A (en) * | 2018-02-28 | 2019-09-12 | 学校法人藤田学園 | Composition for cancer therapy containing compound having kat inhibitory activity |
| CN115944627B (en) * | 2023-01-13 | 2025-03-14 | 山西医科大学 | Pharmaceutical composition for treating breast cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1153113A (en) * | 1967-01-20 | 1969-05-21 | Chugai Pharmaceutical Co Ltd | Method of Treating Hemolytic Streptococci and the Resultant Preparation containing the same |
| US5620850A (en) * | 1994-09-26 | 1997-04-15 | President And Fellows Of Harvard College | Molecular recognition at surfaces derivatized with self-assembled monolayers |
| US6011021A (en) * | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| JP4223804B2 (en) * | 2000-10-03 | 2009-02-12 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | In situ dilution with magnetic force |
| US20020164611A1 (en) * | 2000-11-15 | 2002-11-07 | Bamdad R. Shoshana | Oligonucleotide identifiers |
| AU2002248909A1 (en) * | 2000-11-15 | 2002-05-27 | Minerva Biotechnologies Corporation | Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition |
-
2001
- 2001-11-15 AU AU2002248909A patent/AU2002248909A1/en not_active Abandoned
- 2001-11-15 WO PCT/US2001/046221 patent/WO2002039999A2/en not_active Ceased
- 2001-11-15 US US10/003,681 patent/US20020156112A1/en not_active Abandoned
-
2003
- 2003-11-14 US US10/714,452 patent/US20050014784A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002039999B1 (en) | 2004-04-15 |
| US20050014784A1 (en) | 2005-01-20 |
| WO2002039999A2 (en) | 2002-05-23 |
| WO2002039999A3 (en) | 2003-02-20 |
| US20020156112A1 (en) | 2002-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001234128A1 (en) | Novel imidazoline compounds | |
| AU2002333524A1 (en) | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors | |
| AU2002214163A1 (en) | Pyridyl-substituted triazoles as tgf inhibitors | |
| AU2001289751A1 (en) | Selective pde 2 inhibitors, used as medicaments for improving cognition | |
| AU2001256769A1 (en) | Triazole derivatives | |
| AU2002248909A1 (en) | Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition | |
| AU2001262150A1 (en) | 2-(nitrogen-heterocyclic)pyrimidone derivatives | |
| WO2001030781A3 (en) | INHIBITORS OF αLβ2 MEDIATED CELL ADHESION | |
| AU2001241927A1 (en) | Inhibitors of p38-alpha kinase | |
| ZA200110254B (en) | Process for the preparation of herbicidal derivatives. | |
| AU2000223275A1 (en) | Novel triazole derivatives | |
| AU2002216314A1 (en) | Heterocyclic angiogenesis inhibitors | |
| AU3429700A (en) | Substituted benzoylpyrazoles as herbicides | |
| AU2002230531A1 (en) | Use of fgf-19 for inhibiting angiogenesis | |
| MXPA03008205A (en) | Process for the preparation of imidazole compounds. | |
| AU2002356180A1 (en) | Methods for inhibiting angiogenesis | |
| AU2002241211A1 (en) | Imidazo-triazine derivatives as pde 5 inhibitors | |
| AU2002339192A1 (en) | 1,2,4-triazole derivatives containing a sulphamate group as aromatase inhibitors | |
| AU2002349621A1 (en) | Angiogenesis inhibitor | |
| AU2002214976A1 (en) | Process for the preparation of benzotriazoles | |
| AU2001290254A1 (en) | Imidazole derivatives or their salts | |
| AU3152201A (en) | Self-leveling coating compound | |
| AU2110201A (en) | Release coating for tapes | |
| AU3971700A (en) | Cyclobutene-3,4-dione derivatives as inhibitors of phosphodiesterase | |
| AU2001295952A1 (en) | Novel remedies or preventives for angiostenosis |